GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » JW (Cayman) Therapeutics Co Ltd (HKSE:02126) » Definitions » Price-to-Owner-Earnings

JW (Cayman) Therapeutics Co (HKSE:02126) Price-to-Owner-Earnings : (As of Jun. 05, 2024)


View and export this data going back to 2020. Start your Free Trial

What is JW (Cayman) Therapeutics Co Price-to-Owner-Earnings?

As of today (2024-06-05), JW (Cayman) Therapeutics Co's share price is HK$2.32. JW (Cayman) Therapeutics Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings or its related term are showing as below:


HKSE:02126's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.78
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-05), JW (Cayman) Therapeutics Co's share price is HK$2.32. JW (Cayman) Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-2.05. Therefore, JW (Cayman) Therapeutics Co's PE Ratio for today is At Loss.

As of today (2024-06-05), JW (Cayman) Therapeutics Co's share price is HK$2.32. JW (Cayman) Therapeutics Co's EPS without NRI for the trailing twelve months (TTM) ended in was HK$-1.56. Therefore, JW (Cayman) Therapeutics Co's PE Ratio without NRI for today is At Loss.


JW (Cayman) Therapeutics Co Price-to-Owner-Earnings Historical Data

The historical data trend for JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JW (Cayman) Therapeutics Co Price-to-Owner-Earnings Chart

JW (Cayman) Therapeutics Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

JW (Cayman) Therapeutics Co Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings falls into.



JW (Cayman) Therapeutics Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.32/-2.05
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


JW (Cayman) Therapeutics Co  (HKSE:02126) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


JW (Cayman) Therapeutics Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of JW (Cayman) Therapeutics Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


JW (Cayman) Therapeutics Co (HKSE:02126) Business Description

Traded in Other Exchanges
Address
No. 699 Zhong Ke Road, 5F, Building B, Pudong New District, Shanghai, CHN
JW (Cayman) Therapeutics Co Ltd is a clinical-stage cell therapy company in China. It focuses on developing, manufacturing, and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors. Its lead product candidate is relmacabtagene autoleucel, which is a potential superior anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy intended for the treatment of a range of hematological cancers.
Executives
Li Dan 2202 Interest of your spouse
Li Yiping James 2201 Interest of corporation controlled by you
Syracuse Biopharma (cayman) Ii, Ltd. 2501 Other
Bristol-myers Squibb Company 2201 Interest of corporation controlled by you
Celgene Corporation 2201 Interest of corporation controlled by you
Juno Therapeutics, Inc. 2101 Beneficial owner
Syracuse Biopharma (cayman) Ltd. 2501 Other

JW (Cayman) Therapeutics Co (HKSE:02126) Headlines

No Headlines